{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:57:45Z","timestamp":1781636265832,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Natural Science Foundationof China","award":["82303753"],"award-info":[{"award-number":["82303753"]}]},{"name":"the MRC research grant","award":["MR\/V006053\/1"],"award-info":[{"award-number":["MR\/V006053\/1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human adenovirus type 11 (HAdV-11) has several advantages compared with human adenovirus type 5 (HAdV-5), including improved infectivity of tumor cells and the potential for intravenous delivery. Our previous study demonstrated that HAdV-11 efficiently infected various human cancer cell lines including esophageal squamous cell carcinoma (ESCC) cell lines, however the cytotoxicity was not effective in some cell lines. The underlying functional mechanisms for this discrepancy are not clear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Cell viability was assessed using an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2\u00a0H-tetrazolium (MTS) assay, and viral replication was quantified by tissue culture infectious dose 50 (TCID\n                      <jats:sub>50<\/jats:sub>\n                      ) and quantitative polymerase chain reaction (qPCR). Flow cytometry was employed to analyze apoptosis, mitochondrial reactive oxygen species, lipid oxidation, mitochondrial mass, mitochondrial membrane potential, and intracellular Fe\u00b2\u207a levels. Transmission electron microscopy was used for ultrastructural analysis. Protein expression and mitochondrial localization were evaluated by Western blotting and immunofluorescence staining, while reduced glutathione levels were measured using a commercial assay kit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We report here that HAdV-11 exerts its anti-ESCC effects via two pathways. Firstly, via the mitochondrial pathway, HAdV-11 promotes mitochondrial fission, thereby enhancing mitophagy, suppressing glutathione peroxidase 4 expression, and increasing lipid peroxidation, which ultimately induces ferroptosis; interestingly, HAdV-11-induced mitophagy attenuates ferroptosis in this context. Secondly, HAdV-11 triggers both mitophagy and ferroptosis through the mammalian target of rapamycin (mTOR) pathway. Our findings indicate that mitochondrial fission and mTOR signaling are closely associated with HAdV-11-induced cytotoxicity in ESCC cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HAdV-11-induced ferroptosis in ESCC cells involves mitochondrial impairment and the mTOR pathway. These findings provide insights into HAdV-11\u2019s oncolytic mechanisms and suggest strategies for enhancing its therapeutic efficacy in ESCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15735-7","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:47:13Z","timestamp":1771937233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic adenovirus type 11-induced ferroptosis of esophageal squamous cell carcinoma cells involves in mitochondrial impairment and the mTOR pathway"],"prefix":"10.1186","volume":"26","author":[{"given":"Lingling","family":"Si","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa S","family":"Chard Dunmall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenguo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"15735_CR1","doi-asserted-by":"crossref","unstructured":"Dai ZT, Si Y, Xiong SF, Li Y, Ye JQ, Gao QL, et al. Chimeric Ad5\/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency. Cancer Gene Ther. 2025;32(3):418\u2013436.","DOI":"10.1038\/s41417-025-00884-x"},{"key":"15735_CR2","doi-asserted-by":"crossref","unstructured":"Lin DN, Shen YA, Liang TB. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Therapy. 2023;8(1):156.","DOI":"10.1038\/s41392-023-01407-6"},{"issue":"12","key":"15735_CR3","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1128\/JVI.02273-07","volume":"82","author":"J O\u2019Prey","year":"2008","unstructured":"O\u2019Prey J, Wilkinson S, Ryan KM. Tumor antigen LRRC15 impedes adenoviral infection: implications for virus-based cancer therapy. J Virol. 2008;82(12):5933\u20139.","journal-title":"J Virol"},{"issue":"17","key":"15735_CR4","doi-asserted-by":"publisher","first-page":"9183","DOI":"10.1128\/JVI.77.17.9183-9191.2003","volume":"77","author":"A Segerman","year":"2003","unstructured":"Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G, Arnberg N. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol. 2003;77(17):9183\u201391.","journal-title":"J Virol"},{"issue":"1","key":"15735_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nm.2270","volume":"17","author":"H Wang","year":"2011","unstructured":"Wang H, Li ZY, Liu Y, Persson J, Beyer I, Moller T, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2011;17(1):96\u2013104.","journal-title":"Nat Med"},{"issue":"3","key":"15735_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1349-7006.2009.01445.x","volume":"101","author":"M Onimaru","year":"2010","unstructured":"Onimaru M, Ohuchida K, Mizumoto K, Nagai E, Cui L, Toma H, et al. hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells. Cancer Sci. 2010;101(3):735\u201342.","journal-title":"Cancer Sci"},{"key":"15735_CR7","doi-asserted-by":"publisher","unstructured":"Cheng Z, Zhang D, Chen J, Wu Y, Liu X, Si L, et al. A novel viral protein translation mechanism reveals mitochondria as a target for antiviral drug development. bioRxiv 2020:2020.2010.2019.344713. https:\/\/doi.org\/10.1101\/2020.10.19.344713.","DOI":"10.1101\/2020.10.19.344713"},{"key":"15735_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-pathmechdis-012419-032711","volume":"15","author":"DC Chan","year":"2020","unstructured":"Chan DC. Mitochondrial dynamics and its involvement in disease. Annu Rev Pathol. 2020;15:235\u201359.","journal-title":"Annu Rev Pathol"},{"issue":"7","key":"15735_CR9","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.devcel.2021.02.009","volume":"56","author":"MYW Ng","year":"2021","unstructured":"Ng MYW, Wai T, Simonsen A. Quality control of the mitochondrion. Dev Cell. 2021;56(7):881\u2013905.","journal-title":"Dev Cell"},{"key":"15735_CR10","doi-asserted-by":"crossref","unstructured":"Ko HJ, Tsai CY, Chiou SJ, Lai YL, Wang CH, Cheng JT, et al. The phosphorylation status of Drp1-Ser637 by PKA in mitochondrial fission modulates mitophagy via PINK1\/Parkin to exert multipolar spindles assembly during mitosis. Biomolecules. 2021;11(3):424.","DOI":"10.3390\/biom11030424"},{"key":"15735_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcancer.2019.07.015","volume":"66","author":"DP Panigrahi","year":"2020","unstructured":"Panigrahi DP, Praharaj PP, Bhol CS, Mahapatra KK, Patra S, Behera BP, et al. The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics. Sem Cancer Biol. 2020;66:45\u201358.","journal-title":"Sem Cancer Biol"},{"issue":"1","key":"15735_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12943-022-01664-z","volume":"21","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, McGray AJR, Jiang W, Lu B, Kalinski P, Guo ZS. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Mol Cancer. 2022;21(1):196.","journal-title":"Mol Cancer"},{"issue":"7","key":"15735_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381\u201396.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"15735_CR14","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1080\/15548627.2020.1810918","volume":"17","author":"X Chen","year":"2021","unstructured":"Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054\u201381.","journal-title":"Autophagy"},{"issue":"2","key":"15735_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cac2.12250","volume":"42","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhou X, Xie F, Zhang L, Yan H, Huang J, et al. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun. 2022;42(2):88\u2013116.","journal-title":"Cancer Commun"},{"issue":"8","key":"15735_CR16","doi-asserted-by":"publisher","first-page":"102837","DOI":"10.1016\/j.isci.2021.102837","volume":"24","author":"X Kan","year":"2021","unstructured":"Kan X, Yin Y, Song C, Tan L, Qiu X, Liao Y, et al. Newcastle-disease-virus-induced ferroptosis through nutrient deprivation and ferritinophagy in tumor cells. iScience. 2021;24(8):102837.","journal-title":"iScience"},{"key":"15735_CR17","doi-asserted-by":"crossref","unstructured":"Wong HH, Jiang GZ, Gangeswaran R, Wang PJ, Wang JW, Yuan M, et al. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11 (vol 20, pg 306, 2012). Mol Ther. 2023;31(1):300.","DOI":"10.1016\/j.ymthe.2022.11.016"},{"issue":"1","key":"15735_CR18","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","volume":"8","author":"P Wang","year":"2017","unstructured":"Wang P, Li X, Wang J, Gao D, Li Y, Li H, et al. Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun. 2017;8(1):1395.","journal-title":"Nat Commun"},{"issue":"7","key":"15735_CR19","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/15548627.2021.1990515","volume":"18","author":"Y Gong","year":"2022","unstructured":"Gong Y, Tang N, Liu P, Sun Y, Lu S, Liu W, et al. Newcastle disease virus degrades SIRT3 via PINK1-PRKN-dependent mitophagy to reprogram energy metabolism in infected cells. Autophagy. 2022;18(7):1503\u201321.","journal-title":"Autophagy"},{"issue":"9","key":"15735_CR20","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1080\/15548627.2020.1821548","volume":"17","author":"SC da Silva Rosa","year":"2021","unstructured":"da Silva Rosa SC, Martens MD, Field JT, Nguyen L, Kereliuk SM, Hai Y, et al. BNIP3L\/Nix-induced mitochondrial fission, mitophagy, and impaired myocyte glucose uptake are abrogated by PRKA\/PKA phosphorylation. Autophagy. 2021;17(9):2257\u201372.","journal-title":"Autophagy"},{"key":"15735_CR21","doi-asserted-by":"crossref","unstructured":"Liu W, Chen H, Zhu Z, Liu Z, Ma C, Lee YJ, et al. Ferroptosis inducer improves the efficacy of oncolytic virus-mediated cancer immunotherapy. Biomedicines 2022;10(6):1425.","DOI":"10.3390\/biomedicines10061425"},{"issue":"14","key":"15735_CR22","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185(14):2401\u201321.","journal-title":"Cell"},{"key":"15735_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2019.03.002","volume":"66","author":"B Zhou","year":"2020","unstructured":"Zhou B, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang D. Ferroptosis is a type of autophagy-dependent cell death. Sem Cancer Biol. 2020;66:89\u2013100.","journal-title":"Sem Cancer Biol"},{"issue":"3","key":"15735_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2174\/187220808786241042","volume":"2","author":"WT Ji","year":"2008","unstructured":"Ji WT, Liu HJ. PI3K-Akt signaling and viral infection. Recent Patents Biotechnol. 2008;2(3):218\u201326.","journal-title":"Recent Patents Biotechnol"},{"issue":"5","key":"15735_CR25","doi-asserted-by":"publisher","first-page":"e2075","DOI":"10.1002\/rmv.2075","volume":"29","author":"C Qu","year":"2019","unstructured":"Qu C, Zhang S, Li Y, Wang Y, Peppelenbosch MP, Pan Q. Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections. Rev Med Virol. 2019;29(5):e2075.","journal-title":"Rev Med Virol"},{"issue":"2","key":"15735_CR26","doi-asserted-by":"publisher","first-page":"C258","DOI":"10.1152\/ajpcell.00224.2020","volume":"319","author":"KK Singh","year":"2020","unstructured":"Singh KK, Chaubey G, Chen JY, Suravajhala P. Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. Am J Physiol Cell Physiol. 2020;319(2):C258\u201367.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"17","key":"15735_CR27","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1073\/pnas.1321114111","volume":"111","author":"SJ Kim","year":"2014","unstructured":"Kim SJ, Syed GH, Khan M, Chiu WW, Sohail MA, Gish RG, et al. Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. Proc Natl Acad Sci U S A. 2014;111(17):6413\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"41","key":"15735_CR28","doi-asserted-by":"publisher","first-page":"15803","DOI":"10.1073\/pnas.0808249105","volume":"105","author":"GM Cereghetti","year":"2008","unstructured":"Cereghetti GM, Stangherlin A, Martins de Brito O, Chang CR, Blackstone C, Bernardi P, et al. Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. Proc Natl Acad Sci U S A. 2008;105(41):15803\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15735_CR29","doi-asserted-by":"publisher","first-page":"101004","DOI":"10.1016\/j.mam.2021.101004","volume":"81","author":"S Saurav","year":"2021","unstructured":"Saurav S, Tanwar J, Ahuja K, Motiani RK. Dysregulation of host cell calcium signaling during viral infections: emerging paradigm with high clinical relevance. Mol Aspects Med. 2021;81:101004.","journal-title":"Mol Aspects Med"},{"issue":"7","key":"15735_CR30","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1093\/emboj\/cdg153","volume":"22","author":"G Di Pasquale","year":"2003","unstructured":"Di Pasquale G, Chiorini JA. PKA\/PrKX activity is a modulator of AAV\/adenovirus interaction. EMBO J. 2003;22(7):1716\u201324.","journal-title":"EMBO J"},{"key":"15735_CR31","doi-asserted-by":"publisher","first-page":"176913","DOI":"10.1016\/j.ejphar.2024.176913","volume":"981","author":"J Zhang","year":"2024","unstructured":"Zhang J, Chen J, Lin K. Immunogenic cell death-based oncolytic virus therapy: A Sharp sword of tumor immunotherapy. Eur J Pharmacol. 2024;981:176913.","journal-title":"Eur J Pharmacol"},{"key":"15735_CR32","doi-asserted-by":"publisher","first-page":"1038226","DOI":"10.3389\/fimmu.2022.1038226","volume":"13","author":"L Palanivelu","year":"2022","unstructured":"Palanivelu L, Liu CH, Lin LT. Immunogenic cell death: the cornerstone of oncolytic viro-immunotherapy. Front Immunol. 2022;13:1038226.","journal-title":"Front Immunol"},{"issue":"5","key":"15735_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41418-024-01280-y","volume":"31","author":"SI Yamashita","year":"2024","unstructured":"Yamashita SI, Sugiura Y, Matsuoka Y, Maeda R, Inoue K, Furukawa K, et al. Mitophagy mediated by BNIP3 and NIX protects against ferroptosis by downregulating mitochondrial reactive oxygen species. Cell Death Differ. 2024;31(5):651\u201361.","journal-title":"Cell Death Differ"},{"issue":"11","key":"15735_CR34","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1038\/s41418-023-01230-0","volume":"30","author":"PF Yang","year":"2023","unstructured":"Yang PF, Li J, Zhang TY, Ren YX, Zhang QN, Liu RF, et al. Ionizing radiation-induced mitophagy promotes ferroptosis by increasing intracellular free fatty acids. Cell Death Differ. 2023;30(11):2432\u201345.","journal-title":"Cell Death Differ"},{"issue":"1","key":"15735_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41392-021-00609-0","volume":"6","author":"F Xing","year":"2021","unstructured":"Xing F, Xiao J, Wu J, Liang J, Lu X, Guo L, et al. Modulating the tumor microenvironment via oncolytic virus and PI3K Inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma. Signal Transduct Target Therapy. 2021;6(1):275.","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"15735_CR36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bbrc.2011.02.030","volume":"406","author":"V Mohankumar","year":"2011","unstructured":"Mohankumar V, Dhanushkodi NR, Raju R. Sindbis virus replication, is insensitive to Rapamycin and torin1, and suppresses Akt\/mTOR pathway late during infection in HEK cells. Biochem Biophys Res Commun. 2011;406(2):262\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"15735_CR37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1186\/1471-2407-14-551","volume":"14","author":"K Jiang","year":"2014","unstructured":"Jiang K, Li Y, Zhu Q, Xu J, Wang Y, Deng W, et al. Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated Oncolysis in drug-resistant lung cancer cells. BMC Cancer. 2014;14:551.","journal-title":"BMC Cancer"},{"issue":"1","key":"15735_CR38","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41467-021-21841-w","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Swanda RV, Nie L, Liu X, Wang C, Lee H, et al. mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat Commun. 2021;12(1):1589.","journal-title":"Nat Commun"},{"issue":"2","key":"15735_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.15171\/apb.2015.028","volume":"5","author":"M Mohammadzadeh-Vardin","year":"2015","unstructured":"Mohammadzadeh-Vardin M, Habibi Roudkenar M, Jahanian-Najafabadi A. Adenovirus-Mediated Over-Expression of Nrf2 within mesenchymal stem cells (MSCs) protected rats against acute kidney injury. Adv Pharm Bull. 2015;5(2):201\u20138.","journal-title":"Adv Pharm Bull"},{"key":"15735_CR40","doi-asserted-by":"crossref","unstructured":"Daskou M, Fotooh Abadi L, Gain C, Wong M, Sharma E, Kombe Kombe AJ, et al. The role of the NRF2 pathway in the pathogenesis of viral respiratory infections. Pathogens. 2023;13(1):39.","DOI":"10.3390\/pathogens13010039"},{"issue":"24","key":"15735_CR41","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.3748\/wjg.v10.i24.3634","volume":"10","author":"W Lu","year":"2004","unstructured":"Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a Recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol. 2004;10(24):3634\u20138.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"15735_CR42","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","volume":"29","author":"F Nassiri","year":"2023","unstructured":"Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial. Nat Med. 2023;29(6):1370\u20138.","journal-title":"Nat Med"},{"issue":"10","key":"15735_CR43","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"VT Packiam","year":"2018","unstructured":"Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol. 2018;36(10):440\u20137.","journal-title":"Urol Oncol"},{"issue":"1","key":"15735_CR44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13014-020-01593-5","volume":"15","author":"SM O\u2019Cathail","year":"2020","unstructured":"O\u2019Cathail SM, Davis S, Holmes J, Brown R, Fisher K, Seymour L, et al. A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiat Oncol. 2020;15(1):151.","journal-title":"Radiat Oncol"},{"key":"15735_CR45","doi-asserted-by":"publisher","unstructured":"Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One. 2008;3(6):e2409. https:\/\/doi.org\/10.1371\/journal.pone.0002409. PMID: 18560559; PMCID: PMC2423470.","DOI":"10.1371\/journal.pone.0002409"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15735-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15735-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15735-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:47:19Z","timestamp":1781635639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15735-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15735"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15735-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"423"}}